Skip to search formSkip to main contentSkip to account menu

fruquintinib

An orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
The kinase inhibitor fruquintinib offered improved outcomes vs placebo as a third- and fourth-line treatment in advanced non… 
2018
2018
prove their ability to discover and develop follow-on drug contenders with best-in-class potential. First-generation VEGFR… 
2013
2013
Hutchison MediPharma (HMP), the R&D division of the Chinese pharmaceutical and healthcare group Hutchison Chi-Med, has partnered…